Full Text of HB3080 102nd General Assembly
HB3080sam001 102ND GENERAL ASSEMBLY | Sen. Laura Fine Filed: 11/28/2022
| | 10200HB3080sam001 | | LRB102 13965 BMS 41856 a |
|
| 1 | | AMENDMENT TO HOUSE BILL 3080
| 2 | | AMENDMENT NO. ______. Amend House Bill 3080 by replacing | 3 | | everything after the enacting clause with the following:
| 4 | | "Section 5. The Illinois Insurance Code is amended by | 5 | | changing Section 356z.25 as follows: | 6 | | (215 ILCS 5/356z.25) | 7 | | Sec. 356z.25. Coverage for treatment of pediatric | 8 | | autoimmune neuropsychiatric disorders associated with | 9 | | streptococcal infections and pediatric acute onset | 10 | | neuropsychiatric syndrome. A group or individual policy of | 11 | | accident and health insurance or managed care plan that is | 12 | | amended, delivered, issued, or renewed after July 18, 2017 | 13 | | (the effective date of Public Act 100-24) shall provide | 14 | | coverage for treatment of pediatric autoimmune | 15 | | neuropsychiatric disorders associated with streptococcal | 16 | | infections and pediatric acute-onset neuropsychiatric |
| | | 10200HB3080sam001 | - 2 - | LRB102 13965 BMS 41856 a |
|
| 1 | | syndrome, including, but not limited to, the use of | 2 | | intravenous immunoglobulin therapy. | 3 | | No group or individual policy of accident and health | 4 | | insurance or managed care plan shall deny or delay coverage | 5 | | for medically necessary treatment under this Section solely | 6 | | because the insured, enrollee, or beneficiary previously | 7 | | received any treatment, including the same or similar | 8 | | treatment, for pediatric autoimmune neuropsychiatric disorders | 9 | | associated with streptococcal infections or pediatric acute | 10 | | onset neuropsychiatric syndrome, or because the insured, | 11 | | enrollee, or beneficiary has been diagnosed with or receives | 12 | | treatment for an otherwise diagnosed condition. | 13 | | For the purposes of this Section, coverage of pediatric | 14 | | autoimmune neuropsychiatric disorders associated with | 15 | | streptococcal infections and pediatric acute onset | 16 | | neuropsychiatric syndrome shall adhere to the treatment | 17 | | recommendations developed by a medical professional consortium | 18 | | convened for the purposes of researching, identifying, and | 19 | | publishing best practice standards for diagnosis and treatment | 20 | | of such disorders or syndrome that are accessible for medical | 21 | | professionals and are based on evidence of positive patient | 22 | | outcomes. Coverage for any form of medically necessary | 23 | | treatment shall not be limited over a lifetime of an insured, | 24 | | enrollee, or beneficiary or by policy period. Nothing in this | 25 | | Section prevents insurers from requesting treatment notes and | 26 | | anticipated duration of treatment and outcomes. |
| | | 10200HB3080sam001 | - 3 - | LRB102 13965 BMS 41856 a |
|
| 1 | | For billing and diagnosis purposes, pediatric autoimmune | 2 | | neuropsychiatric disorders associated with streptococcal | 3 | | infections and pediatric acute onset neuropsychiatric syndrome | 4 | | shall be coded as autoimmune encephalitis until the American | 5 | | Medical Association and the Centers for Medicare and Medicaid | 6 | | Services create and assign a specific code for pediatric | 7 | | autoimmune neuropsychiatric disorders associated with | 8 | | streptococcal infections and pediatric acute onset | 9 | | neuropsychiatric syndrome. Thereafter, pediatric autoimmune | 10 | | neuropsychiatric disorders associated with streptococcal | 11 | | infections and pediatric acute onset neuropsychiatric syndrome | 12 | | may be coded as autoimmune encephalitis, pediatric autoimmune | 13 | | neuropsychiatric disorders associated with streptococcal | 14 | | infections, or pediatric acute onset neuropsychiatric | 15 | | syndrome. | 16 | | If, at any time, the Secretary of the United States | 17 | | Department of Health and Human Services, or its successor | 18 | | agency, promulgates rules or regulations to be published in | 19 | | the Federal Register or publishes a comment in the Federal | 20 | | Register or issues an opinion, guidance, or other action that | 21 | | would require the State, pursuant to any provision of the | 22 | | Patient Protection and Affordable Care Act (Public Law | 23 | | 111-148), including, but not limited to, 42 U.S.C. | 24 | | 18031(d)(3)(B) or any successor provision, to defray the cost | 25 | | of any coverage for pediatric autoimmune neuropsychiatric | 26 | | disorders associated with streptococcal infections and |
| | | 10200HB3080sam001 | - 4 - | LRB102 13965 BMS 41856 a |
|
| 1 | | pediatric acute onset neuropsychiatric syndrome outlined in | 2 | | this Section, then the requirement that an insurer cover | 3 | | pediatric autoimmune neuropsychiatric disorders associated | 4 | | with streptococcal infections and pediatric acute onset | 5 | | neuropsychiatric syndrome is inoperative other than any such | 6 | | coverage authorized under Section 1902 of the Social Security | 7 | | Act, 42 U.S.C. 1396a, and the State shall not assume any | 8 | | obligation for the cost of coverage for pediatric autoimmune | 9 | | neuropsychiatric disorders associated with streptococcal | 10 | | infections and pediatric acute onset neuropsychiatric | 11 | | syndrome.
| 12 | | (Source: P.A. 100-24, eff. 7-18-17; 100-863, eff. 8-14-18; | 13 | | 101-488, eff. 8-23-19.)
| 14 | | Section 99. Effective date. This Act takes effect upon | 15 | | becoming law.".
|
|